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Mice deficient in central components of classical NF-κB signaling have low levels of 
circulating natural IgM antibodies and fail to respond to immunization with T-independent 
type 2 (TI-2) antigens. A plausible explanation for these defects is the severely reduced 
numbers of B-1 and marginal zone B (MZB) cells in such mice. By using an ethyl-N- 
nitrosourea mutagenesis screen, we identified a role for the atypical IκB protein IκBNS 
in humoral immunity. IκBNS-deficient mice lack B-1 cells and have severely reduced 
numbers of MZB cells, and thus resemble several other strains with defects in classical 
NF-κB signaling. We analyzed mice heterozygous for the identified IκBNS mutation 
and demonstrate that these mice have an intermediary phenotype in terms of levels 
of circulating IgM antibodies and responses to TI-2 antigens. However, in contrast to 
mice that are homozygous for the IκBNS mutation, the heterozygous mice had normal 
frequencies of B-1 and MZB cells. These results suggest that there is a requirement for 
IκBNS expression from two functional alleles for maintaining normal levels of circulating 
natural IgM antibodies and responses to TI-2 antigens.
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inTrODUcTiOn
Innate-like B cells play significant roles in the early defense against pathogens and, at steady state, 
anti-inflammatory mediators, such as IL-10, and polyreactive IgM antibodies are secreted by these 
cell subsets to help maintain homeostasis. There is a clear division of labor between the different 
innate-like B cells. B-1a cells are thought to secrete most of the natural polyreactive antibodies found 
in the serum (1). Innate response activator B cells exert protective effects against sepsis by secreting 
GM-CSF (2). Marginal zone B (MZB) cells, through their location at the interface between the blood 
and the immune system, help initiate responses against blood-borne antigens [reviewed in Ref. (3)]. B 
cells regulate inflammation through various mechanisms, including production of anti-inflammatory 
cytokines, such as IL-10 and IL-35 (4, 5). The main IL-10 producing innate-like B cells, collectively 
named B10, are found within the MZB (5) and B-1a cell subsets (4, 6). Innate-like B cells are also 
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pivotal for the response against viral and bacterial infections (1). 
Particularly, the innate-like B cell subsets B-1b and MZB cells 
are the predominant responding B cells to T-independent type 2 
(TI-2) antigens found on the surface of a number of pathogens, 
such as Streptococcus pneumoniae, Haemophilus influenzae, and 
Neisseria meningitides (3, 7, 8).
In addition to their distinct roles in homeostasis and response 
to different stimuli, the innate-like B cell subsets also have distinct 
developmental pathways. B-1 cells are generated readily from the 
yolk salk, paraaortic splanchnopleura, and liver during early fetal 
development (9, 10), while these organs are less effective at gener-
ating follicular B cells. In contrast, hematopoietic stem cells from 
adult bone marrow predominantly generate follicular B and MZB 
cells (9), collectively referred to as B-2 cells. Immature B cells 
mature in the spleen and undergo selection at various transitional 
stages before becoming naive B cells (11). B-2 cells are continu-
ously replenished from the adult bone marrow and diverge into 
follicular B cells and MZB cells at the transitional B cell stage (12, 
13). B-1 cells may develop from a separate progenitor population 
(14) and mature via a phenotypically distinct B-1 transitional 
B  cell intermediate, which is found at high frequencies in the 
spleen of neonatal mice (15). The different B cell subsets require 
distinct stimuli for development and maintenance. For example, 
MZB cells are dependent on Notch signaling, and therefore mice 
with impaired Notch2 completely lack MZB cells. However, Notch 
signaling is not required for B-1 or follicular B cell development 
(12). The distinct B cell subsets also show different requirements 
for NF-κB signaling (16).
The NF-κB transcription factors, p50 (NF-κB1), p52 (NF-
κB2), p65 (RelA), c-Rel (Rel), and RelB, regulate transcription 
by binding to promoters of target genes. p50 and p52 induce 
gene transcription by forming heterodimers with p65, c-Rel, or 
RelB, all of which contain a transactivation domain. In contrast, 
homodimers of p50 or p52 lack a transactivation domain and 
thus generally function as repressors of transcription. In classical 
NF-κB signaling, the NF-κB transcription factors are sequestered 
in the cytoplasm as dimers of p50:p65 by a protein family known 
as inhibitors of κB (IκB), including IκB-α, IκB-β, IκB-ϵ, and the 
p50 precursor p105. The IκB proteins are characterized by their 
ankyrin repeat structure, which functions to mask nuclear localiza-
tion signals (17). IκB kinases (IKK), IKK-α (IKK1), IKK-β (IKK2), 
and IKK-γ (NF-kappa-B essential modulator, NEMO), target IκBs 
for polyubiquitination and proteasomal degradation, thereby 
releasing the sequestered NF-κB1 p50 to nuclear localization (18, 
19). In lymphocytes, this requires the CARD11, BCL-10, MALT1 
(CBM) complex. Through an alternative NF-κB signaling pathway, 
NF-κB-inducing kinase (NIK) can activate IKK-α, facilitating 
proteasomal processing of NF-κB2 p100. This ultimately leads to 
nuclear localization of NF-κB p52/RelB (20). A number of atypical 
IκB proteins have recently been identified, defined by their ankyrin 
repeat structure and comprise BCL-3, IκBζ, IκBNS, and IκBη. 
Atypical IκB proteins may either augment or repress transcription 
depending on cell type, context, and timing. Recent studies have 
revealed important roles of atypical IκB proteins in lymphopoiesis 
and immunological responses [reviewed in Ref. (21)].
Classical NF-κB signaling is required for the generation of B-1 
cells, particularly the B-1a subset, which is absent in a number 
of mouse strains where this pathway has been ablated [reviewed 
in Ref. (22)]. Reduction in MZB cell numbers is also seen in the 
absence of classical NF-κB signaling, while follicular B cells are 
less affected (23, 24). Although relatively little is known about 
the function of atypical IκB proteins in B cell development, roles 
for BCL-3 and IκBNS have recently been demonstrated. BCL-3 
deficiency leads to increased numbers of MZB cells (25), while 
decreased B-1 and MZB cellularity was observed upon overex-
pression of BCL-3 (26). Absence of functional IκBNS leads to 
reductions in B-1b and MZB cell frequencies (27, 28) and complete 
absence of B-1a cells, while follicular B cell frequencies are intact 
(15, 28). In terms of B cell lymphopoiesis, IκBNS-deficient mice 
thus resemble other mouse strains with impaired classical NF-κB 
signaling. In addition to the role of classical NF-κB signaling in 
B cell development, it is also required for normal function of 
mature B cells. B cells from p50, BCL10, and CARMA1-deficient 
mice display reduced proliferation and antibody production to 
anti-IgM, anti-CD40, or LPS compared to wild-type (wt) cells 
in vitro (29–31).
Mice with impaired classical NF-κB signaling have reduced 
levels of circulating natural IgM and IgG3 antibodies and fail to 
mount antibody responses to TI-2 antigens in vivo. We previ-
ously described that mice lacking functional IκBNS due to a 
mutation in the nfkbid gene (bumble mice) also display reduced 
IgM and IgG3 levels and fail to respond to immunization with 
NP-ficoll (27, 28). Whether the impaired antibody response in 
mice deficient in classical NF-κB pathway signaling is a con-
sequence of the reduced numbers of B-1 and MZB cells or is 
due to defects in B cell function remains unknown. Here, we 
demonstrate that the lack of IκBNS even at the heterozygous 
state (IκBNS+/bmb) led to severely reduced antibody responses 
against TI-2 antigens, suggesting haploinsufficiency for IκBNS 
in the response to such antigens. Interestingly, unlike homozy-
gous bumble mice, the heterozygous mice displayed apparently 
normal frequencies and numbers of MZB and B-1 cells. This 
indicates that the reduced responses to TI-2 antigens in these 
mice are due to a direct requirement of IκBNS in response to B 
cell receptor engagement rather than a secondary effect due to 
lack of responding cells.
MaTerials anD MeThODs
Mice
Mice were housed and bred at the animal research facility, MTC, 
Karolinska Institutet. Bumble mice, generated by N-ethyl-N-
nitrosourea (ENU) mutagenesis of C57BL/6J mice, and their wt 
C57BL/6J counterparts were described previously (28). Animal 
studies were conducted with Committee for Animal Ethics 
(Stockholms Norra Djurförsöksetiska nämnd) approval.
cell Preparation
Splenocytes were prepared as a single cell suspension using a 
70-μm cell strainer. Peritoneal cells were isolated by flushing 
with cold PBS/1% FBS (5–10 ml). Peritoneal cells were discarded 
if contaminated with blood. Cell suspensions were diluted in 
RPMI-1640 supplemented with 2  mM l-glutamine, penicillin 
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(100 IU)–streptomycin (100 μg/ml), and 10% fetal bovine serum 
(complete RPMI). Splenocyte cell suspensions were washed once 
in Ca2+-free Mg2+-free PBS and treated with red blood cell lysis 
buffer before further processing. B cells were isolated from the 
spleen using the B cell isolation kit and from the peritoneal cavity 
using the Pan-B cell isolation kit (Stemcell Technologies). The 
purity of the isolated populations was ≥90%.
immunization
Mice were immunized with 50-μg NP (40)-ficoll (Biosearch 
Technologies) or a 1:10 dilution of Pneumovax® (Merck & Co.) 
corresponding to 0.5 μg of each polysaccharide antigen. The anti-
gens were diluted in PBS and 100 μl was injected intraperitoneally 
(i.p.).
adoptive Transfer
Isolated peritoneal B cells (2 × 106 cells) from wt or heterozygous 
mice were mixed with 50 μg NP (40)-ficoll and injected i.p. into 
bumble mice. Splenic B cells (30 × 106 cells) were injected i.v.
elisa
ELISA was performed by coating ELISA plates (Nunc) with 
polysaccharide antigens: 500 ng/well of NP (25) conjugated with 
BSA (Biosearch Technologies) or the pneumococcal polysaccha-
ride antigens Type 1 161-X™ or Type 3 169-X™ (both ATCC) 
or 1:100 dilution of Pneumovax (corresponding to 50 ng/well of 
each antigen contained in the vaccine). To measure total IgM and 
IgG3 levels, plates were coated with unconjugated anti-IgM or 
anti-IgG3 (Southern Biotech). Plates were incubated overnight 
(4°C). Following washing (PBS + 2% Tween20) and blocking for 
1 h with PBS containing 2% dry milk, serum was added in three-
fold serial dilutions in blocking buffer and incubated for 1.5 h at 
room temperature (RT) before addition of secondary antibody 
HRP-coupled anti-IgM or IgG3 (Southern Biotech). The assay 
was developed with TMB substrate (KPL) followed by 1M H2SO4 
and the OD was read at 450 nm using an Asys Expert 96 ELISA 
reader (Biochrom).
elispot assay for Detection of antibody-
secreting cells
Detection of total IgM and NP-specific IgM producing cells was 
performed using enzyme-linked immunosorbent spot (ELISpot) 
assay. MultiScreen-IP filter plates (Millipore) were pretreated 
with 70% ethanol and washed in sterile PBS. Plates were coated 
with 5 μg/ml anti-mouse IgM (Southern Biotech) or 5 μg/ml of 
NP (25), conjugated with BSA (Biosearch Technologies), diluted 
in PBS, and incubated overnight at 4°C. The following day, 
plates were washed in sterile PBS, blocked in complete RPMI 
medium with 50-μM 2-mercaptoethanol and 10-mM HEPES for 
1 h at 37°C, and the indicated cell numbers added in triplicate. 
Plates were incubated for 17  h at 37°C in 5% CO2. Cells were 
then removed by washing in PBS and 0.1 μg/well of biotinylated 
anti-mouse IgM (Mabtech) diluted in PBS was added to the wells. 
After 2 h of incubation at RT, plates were washed and developed 
with 100 μl of 5-bromo-4-chloro-3-indolyl phosphate/NBT-plus 
substrate (Mabtech). The reaction was stopped when distinct 
spots could be observed, by rinsing the plates extensively in tap 
water. Spots were counted by ELISpot reader (CTL) and analyzed 
using the Biospot suite (CTL).
Flow cytometry
Cells were incubated with Fc block (anti-CD16/32, BD) and 
stained with fluorochrome-conjugated monoclonal antibodies 
in PBS/2% FBS using the following antibodies: CD5 Brilliant 
Violet 421 (S3-7.3), CD19 PE (1D3), CD19 FITC (1D3), CD23 
Brilliant Violet 421 (B3B4), CD21 APC (7G6), CD43 APC (S7) 
(all BD), B220 APC-eFluor 780 (RA3-6B2), CD93 APC (AA4.1) 
(all eBioscience), and IgM FITC (polyclonal) (Southern Biotech). 
Data were analyzed in FlowJo v9.6.4 (Treestar).
statistics
Differences between groups were analyzed by a Mann–Whitney 
test (GraphPad Prism v6.0f).
resUlTs
heterozygous Bumble Mice have reduced 
serum igM levels and responses to the 
Ti-2 antigen nP-Ficoll
In an ENU mutagenesis screen for antibody response defects, we 
identified a role of IκBNS for B cell development and function. We 
observed that mice homozygous for a specific mutation in nfkbid 
lacked responses to the TI-2 antigen NP-ficoll and had reduced 
levels of circulating IgM and IgG3 antibodies (28). These mice, 
named bumble, were found to have a T → G transversion in the 
conserved donor splice site in the fourth intron of nfkbid, the gene 
encoding IκBNS. This mutation is predicted to prevent splicing 
of the fourth intron from the nfkbid transcript, resulting in a 
premature stop codon after exon 4. Such a transcript would likely 
be targeted for nonsense-mediated decay or encode only 65 of 
327 amino acids (aa) encoded by full-length nfkbid, and therefore 
not be expected to retain any function. The phenotype for bumble 
mice was copied in mice with a targeted mutation in the nfkbid 
gene (28) and was similar in IκBNS knockout mice (27). Here, we 
report that mice heterozygous for the bumble mutation displayed 
reduced NP-specific IgM and IgG3 antibody responses after 
NP-ficoll immunization (Figure 1A). Furthermore, when analyz-
ing isolated splenocytes for NP-specific IgM antibody-secreting 
cells (ASC), we observed significantly (p < 0.001) lower numbers 
in bumble heterozygous compared to wt mice (Figure  1B). To 
test if the TI-2 antigen response defect in heterozygous bumble 
mice was due to a B cell intrinsic defect, we transferred isolated 
splenic and peritoneal B cells to bumble mice and immunized 
them with NP-ficoll. Bumble mice that had not received isolated 
B cells did not respond to immunization, whereas bumble mice 
that had received wt B cells did. Bumble mice that had received 
B cells from heterozygous bumble mice had an intermediate 
response to NP-ficoll immunization, suggesting that the defective 
antibody response to TI-2 antigens in heterozygous bumble mice 
is due to a B cell intrinsic defect (Figure 1C). Similarly to bumble 
homozygotes, mice with the heterozygous bumble mutation dis-
played significantly reduced total serum levels of IgM and IgG3 
FigUre 1 | heterozygous bumble mice have reduced serum igM 
levels and responses to Ti-2 antigens. (a) Mice were immunized with 
50 μg of NP-ficoll intraperitoneally and sacrificed after 6 days. NP-specific 
serum IgM and IgG3 were determined by ELISA. (B) NP-specific IgM 
antibody-secreting cells were determined by ELISpot. Left panel displays 
representative wells of wild-type (wt), heterozygous (hets), and bumble 
(bmb). (c) Isolated peritoneal B cells (2 × 106 cells) from wild-type or 
heterozygous bumble mice were mixed with 50-μg NP (40)-ficoll and 
injected i.p. into bumble mice. The recipient bumble mice then received 
splenic B cells (30 × 106 cells) from wild-type or heterozygous mice 
injected i.v. NP-specific serum IgM and IgG3 were determined by ELISA 
6 days later. (D) Total serum IgM and IgG3 were determined by ELISA. 
Figures represent 8- to 16-week-old aged-matched mice with three to 
eight per group and results are representative of three (a,B) or two  
(c) independent experiments. Graphs display mean + SD. Statistically 
significant differences between bumble, bumble heterozygotes, and wt 
mice are indicated by *p < 0.05, **p < 0.01, and ***p < 0.001 by 
Mann–Whitney test.
FigUre 2 | heterozygous bumble mice have fewer igM-secreting 
B cells. Cell suspensions in serial dilutions were plated on ELISpot plates 
coated with anti-IgM. IgM antibody-secreting cells (ASC) in (a) spleen and 
(B) bone marrow. Upper panels display IgM ASCs per 106 cells and lower 
panels indicate mean spot size. Spot size is influenced by the number of 
spots per well. Therefore, wells containing similar numbers of spots across 
groups were used to calculate spot size (range 10–30 spots for bone marrow 
and 30–70 for spleen). Data were compiled from two experiments.
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antibodies (p < 0.05) (Figure 1D). Thus, relative to homozygous 
bumble mice and wt mice, heterozygous bumble mice presented 
with an intermediary phenotype in terms of response to NP-ficoll 
and levels of circulating IgM and IgG3 antibodies.
Fewer igM antibody-secreting cells in 
heterozygous Bumble Mice
We next asked if the reduced IgM levels in heterozygous bum-
ble mice were due to fewer IgM-secreting B cells or if less IgM 
was produced per cell. To assess this, we performed ELISpot 
for total IgM producing splenic and bone marrow B cells. The 
same numbers of cells were plated from wt, heterozygous, and 
homozygous bumble mice. As expected, no IgM ASCs were 
detected from homozygous bumble mice. The fraction of splenic 
B cells spontaneously secreting IgM in heterozygous bumble mice 
was slightly lower than in wt mice, although this difference was 
not statistically significant (p = 0.23) (Figure 2A). The frequency 
of IgM ASCs in bone marrow was significantly lower in heterozy-
gous bumble mice than in wt mice (p < 0.01). As an indication 
of the amount of IgM produced per IgM ASC, we evaluated the 
mean spot size. We observed no measurable differences in mean 
spot size between heterozygous and wt mice (Figure 2B). These 
data indicate that the reduced levels of natural IgM antibodies in 
the serum is due to fewer IgM ASCs in the heterozygous bumble 
rather than less IgM secreted per ASC.
heterozygous Bumble Mice have normal 
Frequencies of the Major B cell subsets
The main responding B cell subsets against TI-2 antigens are 
B-1b cells and MZB cells (3, 7, 8), while B-1a cells are believed 
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to produce most of the natural IgM antibodies found in the 
serum at steady state (1). Homozygous bumble mice had normal 
numbers of follicular B cells, but completely lacked B-1a cells, 
and displayed a severe reduction in the frequencies of B-1b and 
MZB cells (15, 28). Transfer of wt peritoneal cells to bumble mice 
completely restored serum natural IgM levels and partly restored 
the antibody response to immunization with NP-ficoll (15). This 
suggested that the lack of B-1b cells in homozygous bumble mice 
formed the basis for the impaired response to T-independent 
antigens. To investigate if heterozygous bumble mice have defects 
in B cell development, we used the following strategy to pheno-
typically distinguish the major B cell subsets. B220 is expressed 
by all B-2 cells (MZB and follicular B cells), but at lower levels on 
most B-1 cells. CD11b and CD43 are expressed by B-1 cells, and 
CD5 is expressed by the B-1a cell subset. CD23 is expressed by 
B-2 cells, but not MZB cells, while MZB cells express high levels 
of CD21. When analyzing the different B cell subsets in heterozy-
gous bumble mice, we found that neither overall splenic B cell nor 
MZB cell numbers were significantly different between wt mice 
and heterozygous bumble mice. In contrast, mice homozygous for 
the bumble mutation had significantly reduced MZB cell numbers 
as expected (p < 0.01) (Figure 3A). The increased surface IgM 
level seen in homozygous bumble mice (28) was not observed in 
the heterozygous state (Figure  3B). Furthermore, homozygous 
bumble mice have decreased frequencies of transitional T3 B cells 
(15), while in heterozygous mice, the T3 B cell frequencies were 
similar to those of wt mice (Figure 3C). No differences in bone 
marrow B cell progenitor populations were observed between 
wt, homozygous, and heterozygous bumble mice (Figure  3D). 
As we reported previously, homozygous bumble mice completely 
lacked B-1a cells and had significantly reduced B-1b cell frequen-
cies (p <  0.01) (15). In contrast, peritoneal B-1a and B-1b cell 
frequencies were similar in wt and heterozygous bumble mice 
(Figure 4A). Similarly, bone marrow B-1a cell and spleen B-1a 
cell frequencies were indifferent between heterozygous bumble 
and wt mice (Figures  4B,C). Overall, these data indicate that 
the development and maintenance of all the major B cell subsets 
occur normally in heterozygous bumble mice.
impaired antibody response to the Ti-2 
Vaccine Pneumovax in heterozygous 
Bumble Mice
We next investigated if the impaired response to TI-2 antigens in 
heterozygous bumble mice would extend to the clinically relevant 
human polysaccharide vaccine Pneumovax. To this end, wt, het-
erozygous, and homozygous bumble mice were immunized with 
Pneumovax intraperitoneally. By 6 days post-immunization, wt 
mice mounted a strong antibody response against the Pneumovax 
vaccine antigens. No response was observed in homozygous 
bumble mice, while heterozygous bumble mice displayed an 
intermediary response (Figure  5A). We also investigated the 
Pneumovax-elicited responses to the polysaccharide antigens type 
1 161-X (Figure 5B) and type 3 169-X (Figure 5C). Similarly to 
total Pneumovax-specific antibodies, the responses against both 
polysaccharides were significantly diminished in heterozygous 
bumble mice compared to in wt mice (p < 0.01).
DiscUssiOn
The data presented here demonstrate that a heterozygous muta-
tion in IκBNS causes a significant impairment of B cell function. 
Mice that express one wt allele and one allele containing the 
bumble mutation in nfkbid had diminished antibody responses to 
T-independent type II antigens and reduced levels of circulating 
natural IgM and IgG3 antibodies. The bumble mutation causes 
a premature stop codon after exon 4 in the nfkbid gene and the 
resulting transcript encodes only 65 of the 327 aa of the full-length 
IκBNS (28). The resulting mRNA transcript is likely targeted for 
degradation by nonsense-mediated decay. Thus, the spontaneous 
secretion of natural antibodies and responses to TI-2 antigens in 
bumble heterozygotes are likely impaired as a result of haploinsuf-
ficiency for the nfkbid gene.
Previous work has shown that p50−/−, BCL10−/−, and IκBα 
hypermorphic mice fail to respond to immunization with TI-2 
antigens (32, 33), illustrating that this defect is a general feature 
of deficiency in the classical NF-κB signaling pathway. Similar to 
other proteins of the classical NF-κB pathway, IκBNS also plays 
an important role for maintaining normal levels of serum natural 
antibodies and for the antibody response against TI-2 antigens 
(27, 28). Notably, the major B cell subsets responsible for natural 
antibody production and response to TI-2 antigens, B-1 and MZB 
cells are lacking in mice with impaired classical NF-κB signaling, 
which is also similar for mice with non-functional IκBNS (15, 27, 
28). It was therefore interesting that heterozygous bumble mice 
had decreased serum IgM and IgG3 levels and defective responses 
to TI-2 antigens, despite having apparently normal numbers and 
frequencies of B-1 and MZB cells. This suggested that the lack of 
specific B cell subsets is not the sole reason for the reduced levels 
of natural antibodies and response to TI-2 antigens in IκBNS-
deficient mice. Rather, this indicated a more direct role of IκBNS 
for these aspects of immunity downstream of B cell receptor 
signaling. Particularly, the lack of response to TI-2 antigens of 
heterozygous bumble mice may be due to a B cell intrinsic defect 
in activation or ASC differentiation, although it is also possible 
that the BCR repertoire may be altered when IκBNS is only 
expressed from one allele. We did not observe any reduction in 
B-1a, MZB, or follicular B cell numbers in heterozygous bumble 
mice, suggesting that one functioning allele of nfkbid is enough to 
facilitate normal B cell development. However, we cannot rule out 
the possibility that a modest impairment of B cell development is 
masked by homeostatic proliferative mechanisms or altered bone 
marrow output to control distribution of immune cells (34).
There are only few reports of heterozygous mutations in the 
NF-κB pathways leading to loss of B cell function. Hypermorphic 
heterozygous mutations in IκBα cause impaired antibody 
responses (33) and CARMA1-deficient mice lacking CARD 
(ΔCARD) showed defective B cell proliferation at the heterozygous 
state (35). Since ΔCARD was found to act as a dominant-negative 
inhibitor of TCR-induced NF-κB activation, the impaired B cell 
function in heterozygous ΔCARD-deficient mice may be due to 
the truncated CARMA1 protein interfering with function of the 
wt protein (36). Protein kinase C-β (PKCβ) initiates a phospho-
rylation cascade that activates the CBM complex downstream 
BCR signaling. Heterozygous missense mutations in the gene 
FigUre 3 | heterozygous bumble mice have normal frequencies of the major B cell subsets. Total B cells, marginal zone B cells (MZB), and transitional B 
cells were stained by FACS in wild-type (wt), heterozygous (hets), and bumble (bmb) mice. (a) Left panel: representative staining of marginal zone B cells (MZB, 
B220+, CD23−, and CD21hi) and follicular B cells (B220+, CD23+, and CD21+). Right panel: total B cell (B220+) and MZB cell numbers. (B) Representative staining of 
surface IgM (sIgM) on wt (black), heterozygous (blue), and bumble (blue) follicular B cells. (c) Splenic transitional B cells (B220+ and CD93+), further subdivided into 
T1 (CD23−IgM+), T2 (CD23+IgM+), and T3 (CD23+IgMlo). (D) Bone marrow B cell progenitors, pro B (B220+CD43+CD19+CD93+), pre B (B220+CD43−IgM−CD93+), 
immature B (B220+CD43−IgM+CD93+), and mature B cells (B220+CD43−IgM+CD93−). For transitional and progenitor B cell gating strategy, see Figure S1 in 
Supplementary Material. Figures represent 8- to 16-week-old mice with four to seven mice per group, and results are representative of at least two independent 
experiments. Graphs display mean + SD. Statistically significant differences between bumble, bumble heterozygotes, and wt mice are indicated by *p < 0.05 by 
Mann–Whitney test.
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FigUre 4 | heterozygous bumble mice have normal frequencies of B-1 cells. Wild-type (wt), heterozygous bumble (hets), and bumble (bmb) cells were 
stained for B-1 cells. (a) Peritoneal B-1 cells identified as CD19hiB220loCD43+ (B1b) and CD19hiB220loCD43+CD5+ (B1a). B-1a cells were identified as CD93-IgM+C
D19hiB220loCD5+ in (B) bone marrow and (c) spleen. Representative stainings of B-1a cells in bone marrow and spleen are shown in Figure S2 in Supplementary 
Material. Figures represent 8- to 16-week-old mice with four to seven mice per group, and results are representative of at least two independent experiments. 
Graphs display mean + SD. Statistically significant differences between bumble, bumble heterozygotes, and wt mice are indicated by *p < 0.05 and **p < 0.01 by 
Mann–Whitney test.
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encoding PKCβ were found to lead to impaired antipolysac-
charide antibody responses and reduced natural antibody levels, 
despite apparently normal B cell development (37).
Several clinical cases with mutations in NF-κB proteins have 
demonstrated important roles of both the classical and alternative 
NF-κB signaling pathways for B cell development and function 
in humans. Hypermorphic mutations in the gene encoding 
IκBα lead to impaired phosphorylation-driven degradation of 
the mutant protein and thereby reduced NF-κB signaling (38). 
Hypermorphic heterozygous mutations in IκBα cause ectoder-
mal dysplasia with immunodeficiency as evidenced by recurrent 
severe infections (38, 39). These patients have increased numbers 
of B and T cells, but display both B and T cell functional defects 
(39). Notably, the patient symptoms and lymphocyte functional 
defects could to a large extent be reproduced when introducing 
one of the hypermorphic IκBα mutations (S32I) to mice (33). 
Similar symptoms to IκBα hypermorphs are evident in patients 
with NEMO deficiency and B cells from these patients do not 
respond to CD40 ligation (40). More recently, several patients with 
mutations in the CBM complex have been described. Combined 
immunodeficiency (CID) resulting from impaired classical 
NF-κB signaling due to CARMA1 deficiency was associated with 
hypogammaglobulinaemia, impaired BAFF-R expression and a 
block of B cell maturation at the transitional B cell stage (41, 42). 
Human MALT1 deficiency, also manifested by CID, was associ-
ated with lack of MZB cells and failure to respond to Pneumovax 
vaccination (43, 44), a phenotype that is very similar to that 
seen in the corresponding mouse model (45). Rapid advances 
FigUre 5 | heterozygous bumble mice have reduced antibody 
responses to immunization with pneumococcal polysaccharide 
vaccine. Wild-type (wt), heterozygous bumble (hets), and bumble (bmb) 
mice were immunized with Pneumovax pneumococcal polysaccharide 
vaccine and sacrificed after 6 days. Serum antibody responses were 
analyzed by ELISA against (a) Pneumovax, (B) type 1 polysaccharide antigen 
161-X, and (c) type 3 polysaccharide antigen 169-X. Figures represent 14- 
to 16-week-old mice with five mice per immunized group, and results are 
representative of two independent experiments. Graphs display mean + SD. 
Statistically significant differences between bumble, bumble heterozygotes, 
and wt mice are indicated by **p < 0.01 by Mann–Whitney test.
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in identifying genes underlying human immunodeficiencies will 
reveal if also IκBNS plays a role in this disease group.
So far, there are few reports of heterozygous mutations in 
the NF-κB pathway leading to immunodeficiency in humans. 
Heterozygous gain-of-function mutations in the gene encoding 
CARMA1 were shown to result in constitutive NF-κB activity and 
are manifested by lymphocytosis but impaired memory B  cells 
and low TI-2 responses (46, 47). It is interesting to speculate if 
heterozygous mutations in genes encoding components of BCR 
signaling, including classical NF-κB pathway mediators, may con-
tribute to the observed variability in antipolysaccharide immune 
responses in the human population (48, 49). We describe here that a 
heterozygous mutation in the nfkbid gene encoding the atypical IκB 
protein IκBNS led to reduced steady state IgM and IgG3 antibody 
levels and impaired response to vaccination with TI-2 antigens in 
mice. Heterozygous mutations in genes of the NF-κB pathway could 
potentially lead to haploinsufficiency for B cell function, resulting in 
lower antibody responses to vaccination and increased susceptibil-
ity to infection, which should be considered in future studies.
aUThOr cOnTriBUTiOns
GKP designed and performed the experiments and wrote the 
manuscript. MÁ, JS, and SK performed the experiments. CA and 
BB designed the experiments. GKH designed the experiments and 
wrote the manuscript. All authors have approved the manuscript.
acKnOWleDgMenTs
We are grateful to the personnel at the animal facility at the 
Department of Microbiology, Tumor and Cell Biology at the 
Karolinska Institutet. This work was supported by grants from the Bill 
& Melinda Gates Foundation (GKH and BB), the Swedish Research 
Council (GKH), and David och Astrid Hageléns stiftelse (GKP).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00065
FigUre s1 | gating strategy for identifying transitional and progenitor 
B cells. (a) Representative staining of wild type splenocytes for transitional B 
cells (CD93+B220+) and the transitional B cell populations gated as indicated. 
(B)  Representative staining of wild type bone marrow for progenitor and mature B 
cell populations. Pro B (B220+CD43+CD19+CD93+), pre B (B220+CD43-IgM-CD93+), 
immature B (B220+CD43-IgM+CD93+), and mature B cells (B220+CD43-IgM+CD93-).
FigUre s2 | representative stainings of bone marrow and spleen B-1a 
cells. B-1a cells were identified as cD93-igM+cD19hiB220locD5+ in (a) 
bone marrow and (B) spleen.
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